ATRT-23. SMARCB1-DEPENDENCIES IN ATYPICAL TERATOID/RHABDOID TUMOURS: A STRATEGY FOR PRE-CLINICAL THERAPEUTIC TARGET IDENTIFICATION IN THE ABSENCE OF ACTIONABLE MUTATIONS

ATRTs have low mutation rates and few classically-actionable variants to direct molecularly targeted therapies; loss of SMARCB1 is the sole recurrent mutational event in >90% of ATRTs. We have designed and implemented a genome-scale strategy for target identification and prioritization in tumors...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Finetti, Martina Anna, Selby, Matthew p, Pons, Alicia del-Carpio, Batting, Sarah, Wood, James A, Barker, James M, Smith, Amanda, Crosier, Stephen, Bashton, Matthew, Pickles, Jessica C, Fairchild, Amy R, Avery, Aimee, O’Hare, Patricia, Pizer, Barry, Brennan, Bernadette, Lowis, Stephen, Hargrave, Darren, Jacques, Thomas S, Bailey, Simon, Clifford, Steven C, Williamson, Daniel
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012497/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.021
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars